These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23313887)

  • 21. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine.
    Johansson BE
    Vaccine; 1999 Apr; 17(15-16):2073-80. PubMed ID: 10217609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA fusion vaccines incorporating IL-23 or RANTES for use in immunization against influenza.
    Williman J; Young S; Buchan G; Slobbe L; Wilson M; Pang P; Austyn J; Preston S; Baird M
    Vaccine; 2008 Sep; 26(40):5153-8. PubMed ID: 18456374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
    Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
    Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the vaccine potential of an influenza A viral hemagglutinin and matrix double insertion DNA plasmid.
    Xie H; Liu T; Chen H; Huang X; Ye Z
    Vaccine; 2007 Nov; 25(44):7649-55. PubMed ID: 17913307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK; Tomar P; Sharma V; Dixit VK
    Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens.
    Wu Q; Fang L; Wu X; Li B; Luo R; Yu Z; Jin M; Chen H; Xiao S
    Mol Immunol; 2009 Jul; 46(11-12):2210-7. PubMed ID: 19446339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Construction and immunogenicity of attenuated Salmonella typhimurium harbouring stable DNA vaccine against H5 subtype of avian influenza virus].
    Tang LH; Pan ZM; Cheng NN; Jiao XA; Zhang XM
    Wei Sheng Wu Xue Bao; 2007 Aug; 47(4):662-6. PubMed ID: 17944368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Construction and immunogenicity study of DNA vaccine expressing human H5N1 influenza virus hemagglutinin].
    Huan LF; Yao LH; Chen AJ; Cheng CS; Jia RQ; Tian Q; Bo H; Guo JQ; Wang M; Shu YL; Zhang ZQ
    Bing Du Xue Bao; 2007 Sep; 23(5):366-70. PubMed ID: 17969853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved immune responses against avian influenza virus following oral vaccination of chickens with HA DNA vaccine using attenuated Salmonella typhimurium as carrier.
    Jazayeri SD; Ideris A; Zakaria Z; Yeap SK; Omar AR
    Comp Immunol Microbiol Infect Dis; 2012 Sep; 35(5):417-27. PubMed ID: 22512819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in Mice.
    Song L; Xiong D; Hu M; Kang X; Pan Z; Jiao X
    PLoS One; 2016; 11(3):e0150678. PubMed ID: 26930068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunological evaluation of vector-expressed M2 and HA genes of H5N1 influenza virus in mice].
    Guo J; Yao L; Chen A; Xu Y; Liu X; Shu Y; Zhang Z
    Sheng Wu Gong Cheng Xue Bao; 2010 May; 26(5):649-56. PubMed ID: 20684310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
    Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
    Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein.
    James CM; Abdad MY; Mansfield JP; Jacobsen HK; Vind AR; Stumbles PA; Bartlett EJ
    Vaccine; 2007 Feb; 25(10):1856-67. PubMed ID: 17240000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on antibody responses following neonatal immunization with influenza hemagglutinin DNA or protein.
    Pertmer TM; Robinson HL
    Virology; 1999 May; 257(2):406-14. PubMed ID: 10329551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
    Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus.
    Fossum E; Grødeland G; Terhorst D; Tveita AA; Vikse E; Mjaaland S; Henri S; Malissen B; Bogen B
    Eur J Immunol; 2015 Feb; 45(2):624-35. PubMed ID: 25410055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
    de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
    Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.